AKIP1 accelerates glioblastoma progression through stabilizing EGFR expression.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Kinase Interacting Protein 1 (AKIP1) is overexpressed in various cancers, linked to poor prognosis and malignant functions.
• AKIP1's specific role in glioblastoma (GBM) progression and its underlying mechanisms are not fully understood.

Purpose of the Study:

• To elucidate the mechanism by which AKIP1 contributes to glioblastoma progression.
• To investigate the correlation between AKIP1 expression and glioma pathological grades.

Main Methods:

• Assessed AKIP1 expression in correlation with glioma pathological grades.
• Performed knockdown of AKIP1 to evaluate its impact on GBM cell proliferation, colony formation, and tumorigenicity.
• Investigated the interaction between AKIP1, Yin Yang 1 (YY1), Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1), and Epidermal Growth Factor Receptor (EGFR).

Main Results:

• AKIP1 expression positively correlated with glioma pathological grades.
• Down-regulation of AKIP1 significantly inhibited GBM cell proliferation, colony formation, and tumorigenicity.
• AKIP1 was found to cooperate with YY1 to activate HSP90AA1 transcription, enhancing EGFR stability.
• Overexpression of HSP90α rescued the effects of AKIP1 depletion on EGFR stability and cell proliferation.

Conclusions:

• AKIP1 is a critical oncogenic factor in glioblastoma progression.
• A novel regulatory mechanism involving AKIP1, YY1, HSP90AA1, and EGFR in aberrant EGFR expression in GBM was uncovered.
• Targeting the AKIP1-YY1-HSP90AA1-EGFR axis may offer a therapeutic strategy for glioblastoma.